Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)

Camicia, 2015, Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review, Mol Cancer, 14, 207, 10.1186/s12943-015-0474-2 Pasqualucci, 2011, Analysis of the coding genome of diffuse large B-cell lymphoma, Nat Genet, 43, 830, 10.1038/ng.892 Pasqualucci, 2011, Inactivating mutations of acetyltransferase genes in B-cell lymphoma, Nature, 471, 189, 10.1038/nature09730 Chateauvieux, 2010, Molecular and therapeutic potential and toxicity of valproic acid, J Biomed Biotechnol., 479364 Marchion, 2005, Valproic acid alters chromatin structure by regulation of chromatin modulation proteins, Cancer Res, 65, 3815, 10.1158/0008-5472.CAN-04-2478 Marchion, 2005, Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta, Clin Cancer Res, 11, 8467, 10.1158/1078-0432.CCR-05-1073 Ageberg, 2013, The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death, Am J Transl Res, 5, 170 Shimizu, 2010, HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells, Leukemia, 24, 1760, 10.1038/leu.2010.157 Damm, 2015, Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo, Exp Hematol Oncol, 4, 4, 10.1186/2162-3619-4-4 Cheson, 2007, Revised response criteria for malignant lymphoma, J Clin Oncol, 25, 579, 10.1200/JCO.2006.09.2403 Abrahamsson, 2011, Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry, Leuk Lymphoma, 52, 1929, 10.3109/10428194.2011.587560 Ho, 2007, Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference, Polit Anal, 15, 199, 10.1093/pan/mpl013 Munster, 2009, Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC, Clin Cancer Res, 15, 2488, 10.1158/1078-0432.CCR-08-1930 Maurer, 2014, Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy, J Clin Oncol, 32, 1066, 10.1200/JCO.2013.51.5866 Persky, 2018, A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806, Am J Hematol, 93, 486, 10.1002/ajh.25010